{"id":"NCT01895543","sponsor":"Ferring Pharmaceuticals","briefTitle":"Safety and Tolerability Extension Trial for Patients With Chronic Idiopathic Constipation","officialTitle":"A Multicenter, Open-label, Safety and Tolerability Extension Trial of 5 mg and 10 mg Elobixibat Daily in the Treatment of Chronic Idiopathic Constipation","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-09","primaryCompletion":"2015-05","completion":"2015-05","firstPosted":"2013-07-10","resultsPosted":"2016-05-09","lastUpdate":"2016-05-09"},"enrollment":411,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Idiopathic Constipation"],"interventions":[{"type":"DRUG","name":"Elobixibat 10 mg","otherNames":[]}],"arms":[{"label":"EBX10","type":"EXPERIMENTAL"}],"summary":"Safety and Tolerability Extension Trial for Patients with Chronic Idiopathic Constipation (CIC)","primaryOutcome":{"measure":"Number of Patients With Adverse Events (AEs) and Serious Adverse Events (SAEs)","timeFrame":"For the overall 52-week Treatment Period","effectByArm":[{"arm":"EBX10","deltaMin":241,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":62,"countries":["United States","Belgium","Canada","Czechia","Hungary","Poland","Slovakia","South Africa","Sweden","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":14,"n":409},"commonTop":["Diarrhoea","Abdominal pain"]}}